Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11473385 | 1.00 | CES2 (0.50) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL11353121 | 0.97 | — | — | |
| SCHEMBL1693862 | 0.86 | — | — | |
| SCHEMBL21133342 | 0.78 | NOS2 (0.33) | CES2CES1 | |
| SCHEMBL5787457 | 0.76 | CES2 (0.52) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL4147284 | 0.76 | CES2 (0.52) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL9794317 | 0.72 | — | — | |
| SCHEMBL6263018 | 0.72 | — | — | |
| SCHEMBL9395969 | 0.70 | CES2 (0.41) | CES2CES1HDAC8HDAC6TSHR | |
| SCHEMBL17430884 | 0.70 | CES2 (0.46) | CES2CES1HDAC8HDAC6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4302583-A | BY HEATING THE CORRESPONDING DIMERIC ACYL CYANIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1981-11-24 | — | — | US | claimed |
| EP-0005484-B1 | PROCESS FOR THE PREPARATION OF ACYL CYANIDES | BAYER AG (DE) | 1980-12-10 | — | — | EP | claimed |
| EP-0005484-A1 | Process for the preparation of acyl cyanides | BAYER AG (DE) | 1979-11-28 | — | — | EP | claimed |
| CN-106966908-A | For improving the method by aliphatic cyano group aldehyde reduction amination for the catalytic activity of the catalyst system of aliphatic diamine | 陶氏环球技术有限责任公司 | 2017-07-21 | — | — | CN | disclosed |
| CN-102781905-B | Process for improving the catalytic activity of catalyst systems for reductive amination of aliphatic cyanoaldehydes to aliphatic diamines | 陶氏环球技术有限责任公司 | 2017-03-22 | — | — | CN | disclosed |
| US-9505716-B2 | Pyrrolidine triple reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2016-11-29 | — | — | US | disclosed |
| EP-2200957-B2 | HYDROGENATION OF ALICYCLIC DIALDEHYDES TO ALICYCLIC DIOLS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20160115123-A1 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2016-04-28 | — | — | US | disclosed |
| EP-2974724-A1 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS | Sunovion Pharmaceuticals Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2393357-B1 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC (US) | 2015-08-26 | — | — | EP | disclosed |
| US-9056830-B2 | Pyrrolidine triple reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2015-06-16 | — | — | US | disclosed |
| WO-2010091268-A1 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS | SEPRACOR INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| EP-2200957-A2 | HYDROGENATION OF ALIPHATIC DIALDEHYDES TO ALIPHATIC DIOLS | Dow Global Technologies Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009035838-A2 | HYDROGENATION OF ALIPHATIC DIALDEHYDES TO ALIPHATIC DIOLS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20070213311-A1 | Modulators of 11-beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same | INCYTE CORPORATION | 2007-09-13 | — | — | US | disclosed |
| WO-2007101270-A1 | MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | INCYTE CORPORATION (US) | 2007-09-07 | — | — | WO | disclosed |
| US-4302583-A | BY HEATING THE CORRESPONDING DIMERIC ACYL CYANIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1981-11-24 | — | — | US | disclosed |
| EP-0005484-B1 | PROCESS FOR THE PREPARATION OF ACYL CYANIDES | BAYER AG (DE) | 1980-12-10 | — | — | EP | disclosed |
| EP-0005484-A1 | Process for the preparation of acyl cyanides | BAYER AG (DE) | 1979-11-28 | — | — | EP | disclosed |
| US-4108875-A | REACTING ACYL HALIDE WITH AN ALKALI METAL CYANIDE AND A COPPER(I) SALT IN THE PRESENCE OF A CARBOXYLIC ACID NITRILE WITH HEATING | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DE) | 1978-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213311-A1 | Modulators of 11-beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same | HSD11B1, HSD17B1, HSD3B1 | CES2 603/4885CES1 35/4885HDAC8 1427/4885 |
| US-20160115123-A1 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC6A3 | CES2 92/4885CES1 545/4885HDAC8 3574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.